Cline Christopher R.

CIK 00019431921 companySAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001943192

Recent Transactions

33 trades

Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-12-01$35.01/sh−20,000→ 92,083 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2025-12-01−20,000→ 0 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-12-01$16.23/sh+20,000→ 112,083 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-09-04$19.71/sh−119→ 92,083 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-09-03$18.20/sh−454→ 92,202 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-08-27$17.31/sh−470→ 92,656 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-05-05$21.05/sh−1,784→ 93,126 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-05-02+4,920→ 94,910 total
Exercise/Conversion
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2025-05-02−4,920→ 4,920 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-04-11$13.14/sh−48→ 89,990 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-02-03$20.12/sh−5,192→ 90,038 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-01-31+21,500→ 95,230 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2025-01-31+58,000→ 58,000 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2025-01-22$18.94/sh−865→ 73,730 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-09-09$11.52/sh−2,490→ 74,595 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-09-05+6,750→ 77,085 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-09-04$9.51/sh−514→ 70,335 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-04-11$6.74/sh−54→ 70,849 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-02-01$8.53/sh−3,818→ 70,903 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2024-01-31+65,000→ 65,000 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-01-31+25,000→ 74,721 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2024-01-23$9.07/sh−853→ 49,721 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-09-05$14.71/sh−457→ 50,574 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-05-10$16.59/sh−455→ 51,031 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-04-11$21.49/sh−47→ 51,486 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-02-01$21.75/sh−1,588→ 51,533 total
Award
Travere Therapeutics, Inc.$TVTX
Employee stock option (right to buy)
2023-01-31+54,500→ 54,500 total
Award
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2023-01-31+6,750→ 6,750 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-01-31+20,250→ 53,121 total
Sale
Travere Therapeutics, Inc.$TVTX
Common Stock
2023-01-24$21.90/sh−852→ 32,871 total
Award
Travere Therapeutics, Inc.$TVTX
Common Stock
2022-09-01+5,000→ 33,723 total
Award
Travere Therapeutics, Inc.$TVTX
Employee Stock option (right to buy)
2022-09-01+48,000→ 48,000 total
Award
Travere Therapeutics, Inc.$TVTX
Performance-based restricted stock units
2022-09-01+9,840→ 9,840 total

Companies

Travere Therapeutics, Inc.
CHIEF FINANCIAL OFFICER
$TVTX

Recent Filings

Address

C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300

SAN DIEGO, CA, 92130

View on SEC.gov